Abstract
Microdosing psychedelic drugs, at a level below the threshold to induce hallucinations, is an increasingly common lifestyle practise. However, the effects of microdosing on sleep have not been previously reported. Here we report results from a Phase 1 randomised controlled trial in which 80 healthy adult male volunteers received a six week course of either LSD (10 µg) or placebo with doses self-administered every third day. Participants used a commercially available sleep/activity tracker for the duration of the trial. Data from 3231 nights of sleep showed that on the night after microdosing participants in the LSD group slept an extra 24.3 minutes per night (95% Confidence Interval 10.3 - 38.3 minutes) compared to placebo - with no reductions of sleep observed on the dosing day itself. There were no changes in the proportion of time spent in various sleep stages or in participant physical activity. These results show clear modification of the physiological sleep requirements in healthy volunteers who microdose, and may have implications for the proposed therapeutic effects of microdosing in mood disorders such as major depressive disorder where sleep is frequently disturbed. The clear, clinically significant, changes in objective measurements of sleep observed are difficult to explain as a placebo effect.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Australia New Zealand Clinical Trials Registry (ACTRN12621000436875).
Funding Statement
The research was funded by donations from 3 individual donors and by a research grant from the Health Research Council of New Zealand (Grant No. 20/845 to SM and RS). SM, RS, NH, NA, AJ, FS, and PR have received research funding from MindBio Therapeutics Ltd. to support data analysis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
New Zealand Health and Disability Ethics Committee gave ethical approval for this work (Reference 19/STH/91)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
3
Blogs/Media
Author Videos